NCT07901101Not yet recruitingPhase 4
Starting HIV Prevention Medicine (PrEP) During an Emergency Department Visit With a Peer Navigator
RAPID Response (Revolutionary Access to PrEP In the ED): A Pilot Implementation Study of Peer Navigator-Facilitated, Same-Visit Initiation of Oral HIV Pre-Exposure Prophylaxis in the Emergency Department
Source: ClinicalTrials.gov · Last updated 28 Oct 2026
Brief summary (registry, in English)
The goal of this study is to learn whether adults who visit a hospital emergency department (ED) find it acceptable to start HIV pre-exposure prophylaxis (PrEP) during that same visit, with help from a peer navigator. PrEP is a daily pill that lowers the chance of getting HIV. Many people who could benefit from PrEP use the ED for health care but have no regular doctor, so they may never be offered it. The main questions this study aims to answer are: * Do participants find starting PrEP in the ED acceptable? * How many participants take the first dose, connect with an ongoing PrEP provider, and keep taking PrEP over one year? At Tampa General Hospital, a peer PrEP navigator (a trained study team member) will offer PrEP information to adults in the ED. Adults who agree to join the study and test HIV-negative will: * take their first PrEP pill in the ED while the navigator watches, and leave with a 29-day supply at no cost * choose a community PrEP provider for ongoing care, with help from the navigator * answer short surveys before leaving the ED and by phone at 2-3 days, 30 days, 60 days, 90 days, and 1 year * allow the navigator to confirm follow-up PrEP lab work with their outside provider at about 120 days
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 21 Oct 2026
- Start date
- 1 Nov 2026
- Primary completion date
- 31 May 2027
- Lead sponsor
- University of South Florida
- Diseases
- HIV
- NCT number
- NCT07901101
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 50
- From 1 Nov 2026 to the primary completion date, 31 May 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Currently taking PrEP, or took PrEP in the last 3 months
- Received injectable PrEP in the last 12 months
Other illness
- Positive or indeterminate HIV test result
- Signs or symptoms of acute (recent) HIV infection
- Active hepatitis B infection
- Known allergy to tenofovir or emtricitabine
Lab values
- Creatinine clearance below 60 mL/min
Who the study is looking for
- Age 18 years or older
- Patient in the Tampa General Hospital emergency department
- Negative fourth-generation HIV antigen/antibody test during the emergency department visit
- Medically stable and able to take part in education
- Able to provide informed consent
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tampa General Hospital Coordinator of this site? Confirm its status | Tampa | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.